A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
DRUG: Nilotinib
Safety evaluation assessed by dose limiting toxicity within first cycle of 28 day treatment and AEs within 3 cycles, every first 28 days|Pharmacokinetic (PK) profile of single and multiple doses, day 1 and 15 of cycle 1,day 6, 8, 10, 12, 22 and 28 of cycle 1, day 15 of cycle 2
Anti-leukemic activity within 3 cycles of 28 days treatment, Day 28 cycle 1, 2 and 3, at the time of disease progression, and at the time of study completion|Bone marrow and/or blood assessments to detect the presence of Bcr-Abl transcript and mutational analysis of Bcr-Abl before, during and after therapy., Day 28 cycle 1, 2 and 3, at the time of disease progression, and at the time of study comp
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.